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orthogonal movements, of the nodal areas was initially 5.7 mm ± 2.9 
mm, which was somewhat smaller than the tumor motion (7.8 mm ± 
4.8 mm). The motion of the lymph nodes decreased during therapy (5.8 
mm after 1 week and 5.3 mm after 2 weeks) but was not statistically 
signiﬁcant different. No difference in motion and motion changes was 
observed between the locations of the lymph nodal areas.
Conclusion: A large variability of changes in nodal volume between 
the patients was observed, but is not clinically relevant since the vol-
umes and hence the volume changes are small. The motion of the nodal 
areas is smaller than the tumor motion and does not change during 
therapy. Therefore smaller internal margins can be applied for the nodal 
areas compared to the internal margin for the primary tumor.
PD5-1-8 Technical Advances on Radiation Therapy, Thu, 12:30 - 14:15
4D CT imaging impacts lung volume definitions and dose-volume 
relationships in radiation treatment of non-small cell lung cancer
Kang, Yixiu; Bucci, M. Kara; Liao, Zhongxing; Liu, Helen H.; Tucker, 
Susan L.; Chang, Joe Y.; Komaki, Ritsuko; Cox, James D.; Mohan, 
Radhe; Dong, Lei 
M.D. Anderson Cancer Center, Houston, TX, USA
Purpose: To characterize lung volume deﬁnitions at various CT 
imaging conditions for advanced non-small-cell lung cancer (NSCLC) 
patients. Due to respiratory motion, lung volumes measured by CT im-
aging can exhibit signiﬁcant volumetric variations, which can affect the 
assessment of dose-volume relationships for radiotherapy. The goal of 
this study was to quantify the range of uncertainties in the dose-volume 
relationships and suggest a uniﬁed correction procedure. 
Methods: Forty stage III/IV NSCLC patients were randomly selected 
for this study. For all patients, a fast CT scan and a 4D CT scan were 
acquired under natural breathing conditions. The fast CT scan (free 
breathing, or FB) represents the typical clinical practice for CT-based 
radiotherapy treatment planning. The 4D CT scan represents the state-
of-art volumetric imaging technique to explicitly include respiratory 
motion. We deﬁne the lung volumes measured in 4D CT at the end of 
inspiration and at the end of expiration as end inspiratory volume (EIV) 
and end expiratory volume (EEV), respectively. The percent of vol-
umes at 5Gy (V5), 20Gy (V20), and 50Gy (V50) were calculated and 
compared for each volume deﬁnition at FB, EEV, EIV, and a specially 
computed average density volume from 4D CT. 
Results: The total lung EIV was on average 13.9% larger than the EEV 
(1SD 5.1%; range: 5.7% to 28%). While the average density of the 
lung at the end of inspiration was 8% lower than the density of the lung 
at the end of expiration, the total mass enclosed in the lung volume 
was 4.6% higher at the end of inspiration than at the end of expira-
tion, possibly due to the blood inﬂow caused by the negative pressure. 
There was an excellent linear relationship between the density ratio 
and the volume ratio at the two breathing extremes among all patients 
(R=0.86; p<0.0001). We found a strong volume impact to the dose-vol-
ume relationship. The V5, V20, and V50 between EIV and EEV varied 
from -15% to +12%, -21% to +17%, and -6% to +3%, respectively. 
The V5, V20, and V50 deﬁned on FB CT scans were systematically 
smaller than those deﬁned in EEV (average=-1.9% for V5; -1.3% for 
V20; and -0.8% for V50) and varied signiﬁcantly (range from -12% to 
+1%), representing the uncertainties in the dose-volume analysis. These 
variations were primary due to volume differences at different breath-
ing phases. The impact of dose distribution by anatomy changes was 
minimal (V5, V20, and V50 variations were less than 1% for the same 
volume deﬁnition). We found that the use of a simple scaling factor can 
effectively correct or convert the dose-volume parameters from one 
phase to another using the population data obtained in this study.
Conclusions: Signiﬁcant variations in dose-volume parameters were 
found in current practice when using different volume deﬁnitions. 
We recommend reporting dose-response data on standardized volume 
deﬁnitions (such as the end of expiration, which is more nature for indi-
vidual patients). Parameters found in this study can be used to convert 
these dose-volume parameters from one volume deﬁnition to another 
based on population average.
PD5-2-1 Clinical Data from Radiation Therapy, Thu, 12:30 - 14:15
Effective local control of stage III non-small cell lung cancer 
(NSCLC) with accelerated radiotherapy for patients with 
unfavorable prognostic factors
Ohnishi, Kayoko; Komaki, Ritsuko; Alen, Pamela; Cox, James; Wei, 
Xiong; Liao, Zhongxing 
The UT, MD Anderson Cancer Center, Houston, TX, USA
Purpose: This retrospective study was performed to evaluate the ef-
ﬁcacy and toxicity of accelerated radiotherapy for patients with Stage 
III NSCLC with unfavorable prognostic factors (PF). 
Materials and Methods: Between 1994 and 2004, 113 patients with 
Stage III NSCLC and unfavorable PF were treated with accelerated 
radiotherapy of 45 Gy in 15 fractions over 3 weeks at the University of 
Texas M.D. Anderson Cancer Center. To compare the efﬁcacy of accel-
erated radiotherapy with conventional radiotherapy, 222 patients with 
Stage III NSCLC who received conventional radiotherapy of >60 Gy 
between 1987 and 2005 were identiﬁed. Their medical and radiological 
records were retrospectively reviewed and analyzed for overall survival 
(OS), local-regional control (LRC), disease free survival (DFS) and 
distant metastasis-free survival (DMFS). Acute and late toxicity of 
accelerated radiotherapy with regard to esophagus and lung were also 
analyzed.
Results: Compared to the patients treated with conventional radio-
therapy, the patients treated with accelerated radiotherapy were older 
in age, had poorer PF and received less chemotherapy. The median 
age was 67 (P<0.00001), 91 patients (81%) had a weight loss of >10% 
(P<0.0001) and 43 patients (38%) had Karnofsky performance status 
(KPS) <70 (P<0.0001). 75 patients (66%) received no chemotherapy. 
Median follow-up was 10 months for the accelerated group and 13 
months for the conventional radiotherapy group. OS was statistically 
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higher in patients treated with conventional radiotherapy. OS at 2 and 
5 years for the accelerated radiotherapy group were 16% and 3%, 
respectively, and 44% and 19% for the conventional radiotherapy group 
(P<0.00001). However, there was no statistical difference in LRC, 
DFS and DMFS between the two groups. LRC at 2 and 5 years for the 
accelerated radiotherapy group were 47% and 19%, compared to 48% 
and 37% for the conventional radiotherapy group. DFS at 2 and 5 years 
for the accelerated group were 24% and 10%, 30% and 19% for the 
conventional radiotherapy group. In terms of toxicity, 12 patients (11%) 
had Common Toxicity Criteria for Adverse Events (CTCAE) grade 3 or 
more treatment related pneumonitis. 6 patients (5%) had CTCAE grade 
3 acute esophagitis and only 1 patient had RTOG grade 3 late esopha-
geal toxicity.
Conclusions: In spite of treating the patients with poorer PF, acceler-
ated radiotherapy of 45 Gy in 15 fractions over 3 weeks achieved com-
parable local-regional control for Stage III NSCLC with conventional 
radiotherapy. Toxicity of accelerated radiotherapy was acceptable. 
Accelerated radiotherapy is reasonable strategy for patients who have 
locally advanced NSCLC with unfavorable prognostic factors, since 
their main goal of treatment is to improve their quality of life within a 
limited time. 
PD5-2-2 Clinical Data from Radiation Therapy, Thu, 12:30 - 14:15
Impact of mediastinal nodal mobility on the accuracy of 
transbronchial needle aspiration (TBNA) without real-time 
imaging
Piet, Anna H.1 Lagerwaard, Frank J.2 Kunst, Peter W.3 van Sörnsen de 
Koste, John R.2 Slotman, Ben J.2 Senan, Suresh2 
1 Dept. of Radiation Oncology, Academic Medical Center, Amsterdam, 
The Netherlands 2 Dept. of Radiation Oncology, VU University Medi-
cal Center, Amsterdam, The Netherlands 3 Dept. of Pulmonology, VU 
University Medical Center, Amsterdam, The Netherlands 
Background: The diagnostic yield of TBNA can be highly variable, 
with a meta-analysis reporting the pooled sensitivity and speciﬁcity to 
be only 39% and 99%, respectively. Nodal position is often estimated 
from the distance between the carina and a visible lymph node, as mea-
sured on a diagnostic CT scan. However, breath-hold conventional CT 
scans do not account for nodal motion, and nodal motion may explain 
the lower yields when TBNA is performed without real-time ultrasound 
imaging. We studied mediastinal nodal motion on 4-dimensional (4D) 
CT scans.
Methods: A total of 47 distinct mediastinal nodes were identiﬁed on 
4DCT scans performed for radiotherapy planning in 25 patients with 
lung cancer. Nodes were mainly located at station 4R, 4L, 7 and 2R and 
each identiﬁed node was contoured in all 10 phases of the 4DCT. Nodal 
motion was derived from the displacement of the center of mass in the 
respiratory phases. In order to evaluate whether the distance between 
the center of mass of each node and the carina remained constant dur-
ing the respiratory cycle, this distance was derived for all respiratory 
phases using the coordinates of both structures. 
Results: The mean nodal diameter was 10.2 ± 4.0 mm (1SD) and mean 
nodal volume 1.8 ± 2.3 cc. Mobility was maximal in the cranio-caudal 
axis (mean of 4.7 ± 2.3 mm) and the corresponding medio-lateral and 
ventro-dorsal mobility was 2.8 ± 1.9 mm and 2.4 ± 1.8 mm, respec-
tively. The mean 3-dimensional displacement of nodal center was 6.2 ± 
2.9 mm, and this exceeded 10 mm in 5 nodes (Table 1). The nodal mass 
was constantly present in only 25 ± 14% of the region encompassing all 
nodal positions. The mean variation in cranio-caudal distance between 
all nodes and carina position during respiration was 5.3 ± 2.1 mm 
(range 2.2-10.5 mm). 
Conclusions: Both nodal motion and the varying distance between 
carina and nodal position, may explain the lower diagnostic yields for 
TBNA procedures performed without real-time guidance.
Table 1: Three-dimensional nodal mobility per location studied
PD5-2-3 Clinical Data from Radiation Therapy, Thu, 12:30 - 14:15
Translating research into routine clinical practice: image-guided 
lung stereotactic radiation therapy for unresectable patients with 
early stage lung cancer
Bezjak, Andrea; Franks, Kevin; Purdie, Tom; Pearson, Shannon; 
Brade, Anthony; Cho, John; Kane, Gabrielle; Sun, Alex; David, Payne; 
Bissonnette, Jean-Pierre 
Princess Margaret Hospital, Toronto, ON, Canada
Background: Stereotactic Body Radiation Therapy (SBRT) has 
emerged as a non-invasive treatment option for unresectable early stage 
non-small cell lung cancer (NSCLC), delivering very high radio-abla-
tive doses of RT to the primary tumor. To ensure efﬁcacy of treatment 
and patient safety, high precision planning and careful treatment deliv-
ery under vigilant quality assurance are needed. We present the evolu-
tion of SBRT practice at Princess Margaret Hospital with an emphasis 
on accuracy of treatment set up and veriﬁcation using image-guided 
techniques.
Methods: From Oct 2004 to Feb 2007, we treated 46 patients (pts) 
with T1T2N0MO NSCLC with SBRT (48 tumors were treated). RT 
schedule for peripheral tumors was 60 Gy/3 fractions over 2 weeks (for 
29 tumors, 12 of the pts were part of the RTOG 0236 phase II study). 
When organ at risk tolerance doses were not achievable, either 54 
Gy/3 fr (3 pts) or 48 Gy/4 fr (10 tumors, all T1) was employed. Central 
tumors were treated with a lower dose of 50 Gy/10 fr schedule (6 pts). 
4DCT simulation was acquired in all but 9 pts who were too large for 
the scanner. All tumor and normal tissue contours and ﬁnal plans are 
reviewed in weekly multidisciplinary SBRT rounds. On the treatment 
unit, cone beam CT (CBCT) is used for image guidance with therapist 
manually matching directly to the tumor, adjusting the patient’s posi-
tion for discrepancies >3mm. CBCT is performed for initial localiza-
tion and repeated during treatment to verify the tumor position. We 
compared CBCT soft tissue (tumor) matching to bone matching (which 
would mimic matching used in conventional portal imaging). Patients 
are followed every 3 months with radiological and clinical assessment.
Results: Median pt age was 73 yrs (48-96); mean tumor size was 2.6 
cm (range 0.7-5.7). Median follow-up is 10 mo (range 0-26 mo). Acute 
RT toxicity was generally mild with grade G1 fatigue the most common 
